International journal of radiation oncology, biology, physics · 2025
Ureter Tolerance in Patients Treated with Stereotactic Body Radiation Therapy on Abdominopelvic Lymph Nodes: Analysis on Dose-related Late Effects.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Werkhoven Lucy A, Mattioli Chiara, Milder Maaike T W, Loi Mauro, Nuyttens Joost J
Аннотация
PURPOSE: This study evaluated late ureteral toxicity in relation to dose in patients treated with stereotactic body radiation therapy (SBRT) on abdominopelvic lymph node (A-P LN) oligometastases and assessed differences between planned and received ureteral dose.
METHODS AND MATERIALS: Patients treated between 2011 and 2023 with SBRT on A-P LN oligometastases from various primary tumors were retrospectively reviewed. Toxicity was graded using the Common Terminology Criteria for Adverse Events version 5.0. Dose-volume histogram parameters (maximum dose to the ureter [Dmax] maximum dose to 0.1 cc of the ureter [D0.1cc], and maximum dose to 0.5 cc of the ureter [D0.5cc]) from ureters receiving >10 Gy were extracted and compared with published ureteral constraints (Dmax 108, D0.1cc 108, and D0.1cc 77 Gy equivalent dose of 2 Gy per fraction with a:b ratio of 3 Gy [EQD23]). Interfraction dose variation was derived from patients who were treated with online adaptive SBRT.
RESULTS: The study included 144 patients, of whom 121 had a total of 137 ureters that were treated with <10 Gy. Most patients (85%) received 45 Gy in 5 fractions. The median ureter Dmax and D0.1cc were 60 and 42 Gy EQD23, respectively. No grade (G) ≥ 4 toxicities were observed. Three patients (2%) developed G3 ureteral obstruction, with Dmax values of 121, 97, and 74 Gy EQD23. Five patients (4%) experienced any G of late urinary toxicity, but only 1 of them exceeded the Dmax of 108 Gy EQD23. In total, 31 (23%) patients did not experience late toxicity, despite exceeding this parameter. No significant difference was found between the planned and received ureter dose (D0.1cc 25 vs 22 Gy EQD23,P = .23). The median follow-up was 28 months.
CONCLUSIONS: The incidence of G3 ureteral toxicity after SBRT on A-P LN oligometastases is low (2%). Published dose constraints were violated in 23% of the patients without reported toxicity, suggesting other factors may contribute. Furthermore, no difference was found between the planned and received ureter dose, indicating that the planned dose is a reliable estimate of the dose received.
METHODS AND MATERIALS: Patients treated between 2011 and 2023 with SBRT on A-P LN oligometastases from various primary tumors were retrospectively reviewed. Toxicity was graded using the Common Terminology Criteria for Adverse Events version 5.0. Dose-volume histogram parameters (maximum dose to the ureter [Dmax] maximum dose to 0.1 cc of the ureter [D0.1cc], and maximum dose to 0.5 cc of the ureter [D0.5cc]) from ureters receiving >10 Gy were extracted and compared with published ureteral constraints (Dmax 108, D0.1cc 108, and D0.1cc 77 Gy equivalent dose of 2 Gy per fraction with a:b ratio of 3 Gy [EQD23]). Interfraction dose variation was derived from patients who were treated with online adaptive SBRT.
RESULTS: The study included 144 patients, of whom 121 had a total of 137 ureters that were treated with <10 Gy. Most patients (85%) received 45 Gy in 5 fractions. The median ureter Dmax and D0.1cc were 60 and 42 Gy EQD23, respectively. No grade (G) ≥ 4 toxicities were observed. Three patients (2%) developed G3 ureteral obstruction, with Dmax values of 121, 97, and 74 Gy EQD23. Five patients (4%) experienced any G of late urinary toxicity, but only 1 of them exceeded the Dmax of 108 Gy EQD23. In total, 31 (23%) patients did not experience late toxicity, despite exceeding this parameter. No significant difference was found between the planned and received ureter dose (D0.1cc 25 vs 22 Gy EQD23,P = .23). The median follow-up was 28 months.
CONCLUSIONS: The incidence of G3 ureteral toxicity after SBRT on A-P LN oligometastases is low (2%). Published dose constraints were violated in 23% of the patients without reported toxicity, suggesting other factors may contribute. Furthermore, no difference was found between the planned and received ureter dose, indicating that the planned dose is a reliable estimate of the dose received.